The differential expression of TFAM in the REMBRANDT cohort was analyzed and found to have significantly higher TFAM gene transcript levels in GBM, astrocytoma, and oligodendroglioma than normal controls (p < 0.0001) (64). This evidence concerns the gene TFAM and astrocytoma (excluding glioblastoma).